Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Biologics
IL-2 treatment can be dangerous. Here’s how drug firms are trying to fix it
By addressing problems with interleukin-2's toxicity and half-life, drug companies hope to build a safer, more targeted immunotherapy for cancer or autoimmune diseases
by Megha Satyanarayana
April 4, 2021
| A version of this story appeared in
Volume 99, Issue 12
Credit: Yang H. Ku/C&EN/Shutterstock | Interleukin-2 (yellow) can spur T cells (blue) to become potent cancer killers but the treatment is toxic. Several companies are trying to engineer the small protein to treat cancer, as well as autoimmunity, more safely and effectively.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter